Trials / Unknown
UnknownNCT04218916
Rhodiola Rosea for Coronary Microvascular Disease
The Efficacy and Safety of Rhodiola Rosea in Patients With Coronary Microvascular Disease
- Status
- Unknown
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 114 (estimated)
- Sponsor
- Qilu Hospital of Shandong University · Academic / Other
- Sex
- All
- Age
- 40 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To investigate the effects of rhodiola rosea on coronary flow reserve and symptoms in patients with microvascular angina pectoris, and to evaluate adverse drug reactions. Long-term clinical follow-up of 1 to 3 years was conducted to evaluate the effect of rhodiola rosea on long-term adverse cardiovascular events in patients with coronary microvascular disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rhodiola Rosea Capsules | 0.28g per capsule, 0.56g once (2 capsules), three times a day |
| DRUG | Placebo | 2 placebo capsules once, three times a day |
Timeline
- Start date
- 2020-01-01
- Primary completion
- 2021-01-01
- Completion
- 2023-01-01
- First posted
- 2020-01-06
- Last updated
- 2020-01-06
Source: ClinicalTrials.gov record NCT04218916. Inclusion in this directory is not an endorsement.